EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications

Siva Sundara Kumar Durairajan iD, Abhay Kumar Singh iD, Udhaya Bharathy Saravanan iD, Mayurikaa Namachivayam iD, Moorthi Radhakrishnan, Jian-Dong Huang iD, Rahul Dhodapkar, Hongjie Zhang iD

Viruses · 2023

DOI: 10.3390/v15061231 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Siva Sundara Kumar Durairajan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur 610005, India. Hauptthemen laut MEDLINE: COVID-19, Gastrointestinal Diseases, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Government of India, Research Grants Council of the Hong Kong Special Administrative Region, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical manifestation of COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in the respiratory system of humans is widely recognized. There is increasing evidence suggesting that SARS-CoV-2 possesses the capability to invade the gastrointestinal (GI) system, leading to the manifestation of symptoms such as vomiting, diarrhea, abdominal pain, and GI lesions. These symptoms subsequently contribute to the development of gastroenteritis and inflammatory bowel disease (IBD). Nevertheless, the pathophysiological mechanisms linking these GI symptoms to SARS-CoV-2 infection remain unelucidated. During infection, SARS-CoV-2 binds to angiotensin-converting enzyme 2 and other host proteases in the GI tract during the infection, possibly causing GI symptoms by damaging the intestinal barrier and stimulating inflammatory factor production, respectively. The symptoms of COVID-19-induced GI infection and IBD include intestinal inflammation, mucosal hyperpermeability, bacterial overgrowth, dysbiosis, and changes in blood and fecal metabolomics. Deciphering the pathogenesis of COVID-19 and understanding its exacerbation may provide insights into disease prognosis and pave the way for the discovery of potential novel targets for disease prevention or treatment. Besides the usual transmission routes, SARS-CoV-2 can also be transmitted via the feces of an infected person. Hence, it is crucial to implement preventive and control measures in order to mitigate the fecal-to-oral transmission of SARS-CoV-2. Within this context, the identification and diagnosis of GI tract symptoms during these infections assume significance as they facilitate early detection of the disease and the development of targeted therapeutics. The present review discusses the receptors, pathogenesis, and transmission of SARS-CoV-2, with a particular focus on the induction of gut immune responses, the influence of gut microbes, and potential therapeutic targets against COVID-19-induced GI infection and IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Gastrointestinal DiseasesInflammatory Bowel DiseasesHumansSARS-CoV-2DysbiosisGastrointestinal TractImmunityImmunomodulation

Stichwörter der Autor:innen

COVID-19SARS-CoV-2angiotensin-converting enzyme 2gastroenteritisgut microfloraimmune responsesinflammatory bowel diseasepathogenesistherapeutics

Autor:innen und Institutionen

  • Department of Microbiology, School of Life Sciences, Central University of Tamil Nadu, Tiruvarur 610005, India.
  • Department of Biochemistry, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong 999077, China.
  • CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
  • Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Government of India, Puducherry 605006, India.
  • School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong 999077, China.

ORCID-Profile: Siva Sundara Kumar Durairajan, Abhay Kumar Singh, Udhaya Bharathy Saravanan, Mayurikaa Namachivayam, Jian-Dong Huang, Hongjie Zhang

Förderung

  • Department of Biotechnology, Government of India
  • Research Grants Council of the Hong Kong Special Administrative Region, China

Zitieren

APA

Durairajan, S. S. K., Singh, A. K., Saravanan, U. B., Namachivayam, M., Radhakrishnan, M., Huang, J. D., Dhodapkar, R., & Zhang, H. (2023). Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications. Viruses. https://doi.org/10.3390/v15061231

Vancouver

Durairajan SSK, Singh AK, Saravanan UB, Namachivayam M, Radhakrishnan M, Huang JD, et al. Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications. Viruses. 2023. doi:10.3390/v15061231

BibTeX
@article{Durairajan2023,
  author = {Durairajan, Siva Sundara Kumar and Singh, Abhay Kumar and Saravanan, Udhaya Bharathy and Namachivayam, Mayurikaa and Radhakrishnan, Moorthi and Huang, Jian-Dong and Dhodapkar, Rahul and Zhang, Hongjie},
  title = {Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15061231}
}
Kostenlos starten →